Study guide

9.4 Preterm Labor, PPROM & Cervical Insufficiency

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

9.4 Preterm Labor, PPROM & Cervical Insufficiency

Key Takeaways Explain This Topic AI

Preterm labor (PTL) is defined as regular uterine contractions (>=4 in 20 minutes or >=8 in 60 minutes) accompanied by progressive cervical change (effacement >=80% or dilation >=2 cm) between 20 0/7 and 36 6/7 weeks gestation.

Clinical evaluation utilizes transvaginal cervical length (short cervix <25 mm before 24 weeks) and fetal fibronectin (fFN; high negative predictive value >95–99% for no delivery within 7–14 days, invalidated by digital exam, intercourse, or bleeding within 24 hours).

Evidence-based pharmacotherapy bundles include antenatal corticosteroids (betamethasone 12 mg IM q24h x 2 doses) between 24 0/7 and 33 6/7 weeks (and late preterm 34 0/7 to 36 6/7 weeks), tocolysis for 48 hours (indomethacin <32 weeks; nifedipine 32–34 weeks), and IV magnesium sulfate for fetal neuroprotection (<32 weeks).

Preterm premature rupture of membranes (PPROM; <37 weeks) is confirmed via sterile speculum exam (pooling, nitrazine blue pH >6.5, microscopic ferning); management involves latency antibiotics (ampicillin + erythromycin/azithromycin; amoxicillin-clavulanic acid strictly avoided) and planned delivery at 34 0/7 weeks or sooner if chorioamnionitis occurs.

Cervical insufficiency presents with painless second-trimester dilation; interventions include history-indicated cerclage (12–14 weeks), ultrasound-indicated cerclage (CL <25 mm before 24 weeks in women with prior preterm birth), or vaginal progesterone for asymptomatic short cervix without prior preterm birth.

Last updated: October 2026

Preterm Labor: Diagnostic Criteria & Biomarkers

Preterm labor (PTL) is defined as regular uterine contractions accompanied by cervical change occurring between 20 0/7 and 36 6/7 weeks gestation .

Clinical Diagnostic Criteria

Documented Uterine Contractions: Persistent, regular contractions occurring at a frequency of ≥4 in 20 minutes or ≥8 in 60 minutes , AND

Progressive Cervical Change: Documented cervical effacement ≥80% or cervical dilation ≥2 cm upon initial examination.

Screening & Diagnostic Modalities

When patients present with ambiguous or early symptoms (pelvic pressure, menstrual-like cramping, backache, or altered vaginal discharge), two objective diagnostic tools guide clinical triage:

Transvaginal Ultrasound Cervical Length (TVUS CL):

Performed with an empty maternal bladder, obtaining the shortest reproducible measurement along the endocervical canal without excessive probe pressure.

Normal Cervical Length: Typically measures 35 to 40 mm at 16 to 24 weeks.

Abnormal / Short Cervix: A cervical length <25 mm before 24 weeks gestation represents a short cervix and strongly correlates with spontaneous preterm birth.

Clinical Utility: If CL is >30 mm, spontaneous preterm delivery within 7 days is highly unlikely (<1% to 2%), allowing safe discharge.

Fetal Fibronectin (fFN):

Biological Role: An extracellular matrix glycoprotein produced by trophoblast cells that acts as a biological "glue" binding the fetal chorion to the maternal decidua.

Diagnostic Window: Validated between 22 0/7 and 34 6/7 weeks gestation in symptomatic women with intact membranes and cervical dilation <3 cm.

Clinical Value: Exceptional Negative Predictive Value (>95% to 99%) . A negative fFN (<50 ng/mL) indicates that the patient has a <1% to 5% probability of delivering within the subsequent 7 to 14 days , preventing unnecessary hospitalizations and medication exposure.

False Positive Precautions: fFN testing is invalidated and prone to false positives if the cervix or posterior fornix has been disrupted within the preceding 24 hours by: digital cervical examination, sexual intercourse, transvaginal ultrasound, moderate-to-heavy vaginal bleeding, or application of vaginal lubricants/creams.

Evidence-Based Pharmacologic Triad in Preterm Labor

When preterm labor is confirmed between 24 0/7 and 33 6/7 weeks gestation, clinical management focuses on administering an evidence-based triad of pharmacotherapies designed to optimize neonatal outcomes.

Pharmacologic Category Primary Agent & Dosing Gestational Window Clinical Mechanism & Proven Neonatal Benefits

Antenatal Corticosteroids Betamethasone 12 mg IM q24h × 2 doses, OR Dexamethasone 6 mg IM q12h × 4 doses 24 0/7 to 33 6/7 weeks (and late preterm 34 0/7 to 36 6/7 weeks) Accelerates type II pneumocyte maturation and surfactant production. Reduces respiratory distress syndrome (RDS) by 50%, intraventricular hemorrhage (IVH) , necrotizing enterocolitis (NEC) , and neonatal death. Optimal efficacy 24h to 7d post-dose.

Tocolytic Therapy Indomethacin (25–50 mg PO q4–6h; max 48h) OR Nifedipine (20 mg PO load, then 10–20 mg q4–6h) 24 0/7 to 33 6/7 weeks Relaxes myometrium to prolong pregnancy for 48 hours , providing a critical therapeutic window to complete the corticosteroid course and facilitate maternal transport to a tertiary NICU center.

Neuroprotection Magnesium Sulfate (4 g IV loading dose over 30 min, then 1 g/hr continuous infusion) <32 0/7 weeks in imminent preterm delivery Stabilizes neuronal membranes and prevents microvascular reperfusion injury. Drastically reduces the incidence and severity of cerebral palsy and gross motor dysfunction in surviving neonates.

Tocolytic Agent Selection & Contraindications

Indomethacin (Non-Steroidal Anti-Inflammatory Drug): First-line tocolytic for gestations <32 weeks . Inhibits cyclooxygenase (COX), blocking prostaglandin synthesis.

Maternal Side Effects: Mild nausea, gastritis, and platelet dysfunction.

Fetal Precautions: Prostaglandins maintain fetal ductal patency and renal perfusion. Prolonged use (>48 hours) or administration after 32 weeks can cause premature in utero constriction of the ductus arteriosus (precipitating fetal pulmonary hypertension) and oligohydramnios (secondary to decreased fetal renal output). Treatment is strictly limited to ≤48 hours .

Nifedipine (Calcium Channel Blocker): First-line tocolytic between 32 0/7 and 33 6/7 weeks (and alternative <32 weeks). Blocks L-type calcium channels in myometrial cells, preventing actin-myosin cross-bridging.

Maternal Side Effects: Peripheral vasodilation, maternal flushing, headache, dizziness, mild transient hypotension, and reflex tachycardia.

Terbutaline (Beta-2 Adrenergic Agonist): Utilized for acute, short-term tocolysis (0.25 mg subcutaneously) to treat intrapartum uterine tachysystole. The FDA warns against prolonged subcutaneous or oral maintenance therapy (>48–72 hours) due to severe maternal cardiovascular risks: pulmonary edema, myocardial ischemia, cardiac arrhythmias, and maternal hyperglycemia.

Important

Tocolytic agents do not independently improve long-term neonatal morbidity or mortality, nor do they prolong pregnancy to term. Their sole clinical purpose is to delay delivery for 48 hours , enabling complete antenatal corticosteroid administration and maternal transfer to a facility with a Neonatal Intensive Care Unit (NICU).

Preterm Premature Rupture of Membranes (PPROM)

Preterm premature rupture of membranes (PPROM) refers to spontaneous rupture of the amniotic sac prior to the onset of labor before 37 0/7 weeks gestation . Complications include intra-amniotic infection (chorioamnionitis), umbilical cord prolapse, placental abruption, and neonatal pulmonary hypoplasia.

Diagnostic Evaluation

Diagnostic confirmation relies on a sterile speculum examination :

Avoid Digital Examination: Digital cervical examination must be strictly withheld in PPROM unless the patient is in active, advanced labor, as digital assessment introduces vaginal pathogens into the endocervix, drastically shortening latency and accelerating chorioamnionitis.

The Diagnostic Triad:

Pooling: Direct visualization of clear fluid collecting in the posterior vaginal fornix.

Nitrazine Test: Amniotic fluid is neutral-to-alkaline (pH 7.1 to 7.3), turning yellow nitrazine paper dark blue (indicating pH >6.5; normal vaginal secretions are acidic, pH 3.8 to 4.5). False positives occur with blood, semen, bacterial vaginosis, or alkaline antiseptic soaps.

Ferning (Arborization): A drop of fluid allowed to air-dry completely on a clean glass slide demonstrates a delicate palm-leaf or fern-like crystallization pattern under low-power microscopy, driven by high sodium chloride and protein concentrations in amniotic fluid.

Clinical Management Protocol

For stable pregnancies between 24 0/7 and 33 6/7 weeks gestation without maternal or fetal compromise:

Latency Antibiotic Regimen (7-Day Course): Prolongs latency, decreases chorioamnionitis, and reduces neonatal sepsis, RDS, and IVH:

Initial 48 Hours: Intravenous Ampicillin (2 g q6h) PLUS Intravenous Erythromycin (250 mg q6h) [or single-dose oral Azithromycin 1 g].

Subsequent 5 Days: Oral Amoxicillin (250 mg q8h) PLUS Oral Erythromycin (333 mg q8h) [or oral Azithromycin].

Contraindication Warning: Amoxicillin-clavulanic acid (Augmentin) is strictly contraindicated in PPROM due to a documented, statistically significant increase in neonatal necrotizing enterocolitis (NEC).

Antenatal Corticosteroids: Single course of betamethasone or dexamethasone administered upon admission.

Delivery Timing: Expectant management with daily maternal-fetal surveillance is maintained until 34 0/7 weeks gestation , at which point induction of labor is recommended. Immediate delivery is indicated at any gestational age if overt chorioamnionitis (fever ≥39.0°C or ≥38.0°C with uterine tenderness, maternal/fetal tachycardia, or purulent fluid), placental abruption, cord prolapse, or non-reassuring fetal status occurs.

Cervical Insufficiency & Cerclage Indications

Cervical insufficiency is defined as the inability of the uterine cervix to retain a pregnancy in the absence of clinical contractions, labor, or intrauterine infection. It characteristically presents in the second trimester (typically between 14 and 24 weeks) with painless cervical shortening, effacement, and dilation , leading to prolapsing membranes and pregnancy loss.

Etiology & Risk Factors

Prior mechanical cervical trauma (repeated mechanical dilations during terminations or D&Cs).

Prior cervical surgical excisions (cold knife cone biopsy or large loop excision of the transformation zone [LEEP]).

Congenital uterine anomalies (bicornuate or septate uterus) or maternal in utero diethylstilbestrol (DES) exposure.

Inherited connective tissue disorders (Ehlers-Danlos syndrome).

Management Modalities & Cerclage Placement

Cerclage Type Clinical Indication Timing & Technical Parameters

History-Indicated Cerclage History of ≥1 unexplained second-trimester pregnancy loss related to painless cervical dilation, or prior history-indicated cerclage. Electively placed at 12 to 14 weeks gestation after establishing fetal viability via first-trimester ultrasound.

Ultrasound-Indicated Cerclage Singleton pregnancy with a history of prior spontaneous preterm birth (<34 weeks) who develops a short cervix ( CL <25 mm before 24 weeks ). Placed upon sonographic detection between 16 and 23 6/7 weeks gestation . Not recommended in multiple gestations.

Physical Exam-Indicated (Rescue) Cerclage Painless cervical dilation (cervix open 1–4 cm) with visible prolapsing fetal membranes detected on speculum/manual exam in 2nd trimester. Placed urgently before 24 weeks gestation after ruling out labor, placental abruption, and subclinical intra-amniotic infection.

Tip

In an asymptomatic woman with a singleton pregnancy and no prior history of spontaneous preterm birth who is incidentally found to have a short cervix (CL ≤20–25 mm) on routine second-trimester ultrasound before 24 weeks, vaginal progesterone (200 mg micronized vaginal suppository daily at bedtime) is the first-line therapy. Cervical cerclage is reserved for women with a history of prior spontaneous preterm birth.